Company intelligence / Profile preview

EURRUS Biotech GmbH

Tulln, Austrialifesciencesdirectory.at ↗

Ownership: Private
Development stage: Phase 2

Overview

EURRUS Biotech GmbH has developed an oral small molecule therapy, XC‑8, targeting the histamine receptor pathway for the treatment of mild and moderate asthma. The company completed successful Phase I trials in Austria and Germany and a pivotal Phase II trial at ten centers across Russia. Results showed high efficacy with no significant side effects. As of late 2020/2021, the lead asset was advancing into or pending Phase III clinical evaluation.

Therapeutic areas: Pulmonology
Modalities: Small molecules (notably oral small molecule drug XC-8)Potentially biologics (company claims expertise in both, but pipeline focus on small molecules)
Industry: Biotech

Drug pipeline

1 asset

histamine glutarimide

Partnerships

Pharmenterprise LLC, Moscow – clinical partner for Russian studiesFGK Clinical Research, Munich – CRO partner for European studiesAcademic partners include Karl Landsteiner Institute (Vienna) and ITEM Hannover [Germany] for early phase trials

Beyond the preview

Go deeper on EURRUS Biotech GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EURRUS Biotech GmbH.

Explore the full profile